Fineline Cube

Follow:
14691 Articles
InnoCare's TL1A/IL‑23p19 Bispecific Antibody ICP‑B161 Cleared for Clinical Trials – Fifth Innovative Drug IND of 2026 Targets Inflammatory Bowel Disease
CompanyDrug

InnoCare’s TL1A/IL‑23p19 Bispecific Antibody ICP‑B161 Cleared for Clinical Trials – Fifth Innovative Drug IND of 2026 Targets Inflammatory Bowel Disease

Kangtai Biological Products Initiates Phase I Trial of Adult, Adolescent and Pediatric Acellular Pertussis‑Diphtheria‑Tetanus (Component) Combination Vaccine – First Subject Enrolled
CompanyDrug

Kangtai Biological Products Initiates Phase I Trial of Adult, Adolescent and Pediatric Acellular Pertussis‑Diphtheria‑Tetanus (Component) Combination Vaccine – First Subject Enrolled

China Resources Double‑Crane Subsidiary Clears FDA for DC7001A Capsules – Investigational Therapy Advances Toward Clinical Trials in Systemic Lupus Erythematosus
CompanyDrug

China Resources Double‑Crane Subsidiary Clears FDA for DC7001A Capsules – Investigational Therapy Advances Toward Clinical Trials in Systemic Lupus Erythematosus

China Resources Double‑Crane Subsidiary Secures NMPA Approval for Vortioxetine Hydrobromide API – Vertically Integrating Its Antidepressant Franchise
CompanyDrug

China Resources Double‑Crane Subsidiary Secures NMPA Approval for Vortioxetine Hydrobromide API – Vertically Integrating Its Antidepressant Franchise

AstraZeneca and Daiichi Sankyo's Enhertu Wins NMPA Approval in HER2‑Positive Early Breast Cancer – New Adjuvant Indication and Full Approval of Neoadjuvant Label in China
CompanyDrug

AstraZeneca and Daiichi Sankyo’s Enhertu Wins NMPA Approval in HER2‑Positive Early Breast Cancer – New Adjuvant Indication and Full Approval of Neoadjuvant Label in China

Hansoh Pharmaceutical Resubmits Aumuletinib MAA to the EMA – EGFR‑TKI Application Validated for Two Advanced NSCLC Indications After EU Market Withdrawal
CompanyDrug

Hansoh Pharmaceutical Resubmits Aumuletinib MAA to the EMA – EGFR‑TKI Application Validated for Two Advanced NSCLC Indications After EU Market Withdrawal

Edding Genor's GB268 Wins NMPA IND Approval for Phase II Trial – PD‑1/CTLA‑4/VEGF Trispecific Antibody Plus Chemotherapy Targets First‑Line Advanced Colorectal Cancer
CompanyDrug

Edding Genor’s GB268 Wins NMPA IND Approval for Phase II Trial – PD‑1/CTLA‑4/VEGF Trispecific Antibody Plus Chemotherapy Targets First‑Line Advanced Colorectal Cancer

Sichuan Biokin's Iza‑Bren Combination Therapy Clinical Trial Application Approved by NMPA – EGFR×HER3 Bispecific ADC Advances with Radiotherapy in Locally Advanced Unresectable HNSCC
CompanyDrug

Sichuan Biokin’s Iza‑Bren Combination Therapy Clinical Trial Application Approved by NMPA – EGFR×HER3 Bispecific ADC Advances with Radiotherapy in Locally Advanced Unresectable HNSCC

Transcenta Granted Chinese Invention Patent for Anti‑CLDN18.2 Antibodies – Protecting the Companion Diagnostic for Osemitamab (TST001) in Gastric Cancer
CompanyDrug

Transcenta Granted Chinese Invention Patent for Anti‑CLDN18.2 Antibodies – Protecting the Companion Diagnostic for Osemitamab (TST001) in Gastric Cancer

Genentech Reports One‑Year Phase III Data for Vamikibart in Uveitic Macular Edema – MEERKAT and SANDCAT Support Rapid, Sustained Vision Improvement
CompanyDrug

Genentech Reports One‑Year Phase III Data for Vamikibart in Uveitic Macular Edema – MEERKAT and SANDCAT Support Rapid, Sustained Vision Improvement

Leads Biolabs' LBL‑024 Granted Second FDA Fast Track Designation – Bispecific PD‑L1/4‑1BB Antibody Advances in First‑Line Advanced Biliary Tract Cancer
CompanyDrug

Leads Biolabs’ LBL‑024 Granted Second FDA Fast Track Designation – Bispecific PD‑L1/4‑1BB Antibody Advances in First‑Line Advanced Biliary Tract Cancer

Novo Nordisk to Withdraw All Forms of Levemir in the UK by End‑2026 – DHSC Issues National Patient Safety Alert Mandating Insulin Switches
CompanyDrug

Novo Nordisk to Withdraw All Forms of Levemir in the UK by End‑2026 – DHSC Issues National Patient Safety Alert Mandating Insulin Switches